Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Virginia, United States.
Curr Pharm Des. 2020;26(30):3760-3767. doi: 10.2174/1381612826666200721002735.
Endothelial dysfunction is a hallmark of type 2 diabetes that can have severe consequences on vascular function, including hypertension and changes in blood flow, as well as exercise performance. Because endothelium is also the barrier for insulin movement into tissues, it acts as a gatekeeper for transport and glucose uptake. For this reason, endothelial dysfunction is a tempting area for pharmacological and/or exercise intervention with insulin-based therapies. In this review, we describe the current state of drugs that can be used to treat endothelial dysfunction in type 2 diabetes and diabetes-related diseases (e.g., obesity) at the molecular levels, and also discuss their role in exercise.
内皮功能障碍是 2 型糖尿病的一个标志,它会对血管功能产生严重影响,包括高血压和血流变化,以及运动表现。因为内皮也是胰岛素进入组织的屏障,所以它是运输和葡萄糖摄取的守门员。出于这个原因,内皮功能障碍是一个有吸引力的领域,可以进行药理学和/或运动干预,以胰岛素为基础的治疗。在这篇综述中,我们描述了目前可用于治疗 2 型糖尿病和糖尿病相关疾病(如肥胖症)的药物在分子水平上的内皮功能障碍的状态,并讨论了它们在运动中的作用。